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Cancer researchers have been looking for ways to harness the immune system and to rein-
state immune surveillance, to kill cancer cells without collateral damage. Here we scan
current approaches to targeting the immune system against cancer, and emphasize our
own approach. We are using chemical vectors attached to a speciﬁc ligand, to introduce
synthetic dsRNA, polyinosine/cytosine (polyIC), into tumors.The ligand binds to a receptor
protein that is overexpressed on the surface of the tumor cells. Upon ligand binding, the
receptor complex is internalized, introducing the polyIC into the cell. In this fashion a large
amount of synthetic dsRNA can be internalized, leading to the activation of dsRNA-binding
proteins, such as dsRNAdependent protein kinase (PKR),Toll-like receptor 3 (TLR3), retinoic
acid-inducible gene I (RIG-1), and melanoma differentiation-associated gene 5 (MDA5).The
simultaneous activation of these signaling proteins leads to the rapid demise of the tar-
geted cell and to cytokine secretion. The cytokines lead to a strong bystander effect and
to the recruitment of immune cells that converge upon the targeted cells. The bystander
effects lead to the destruction of neighboring tumor cells not targeted themselves by the
vector. Normal cells, being more robust than tumor cells, survive. This strategy has sev-
eral advantages: (1) recruitment of the immune system is localized to the tumor. (2) The
response is rapid, leading to fast tumor eradication. (3) The bystander effects lead to the
eradication of tumor cells not harboring the target. (4) The multiplicity of pro-death signal-
ing pathways elicited by PolyIC minimizes the likelihood of the emergence of resistance.
In this chapter we focus on EGFR as the targeted receptor, which is overexpressed in
many tumors. In principle, the strategy can be extended to other tumors that overexpress
a protein that can be internalized by a ligand, which can be a small molecule, a single chain
antibody, or an afﬁbody.
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INTRODUCTION
A great boost for cancer research was rendered in 1971,when Pres-
ident Nixon signed the National CancerAct. This historic moment
was a turning point in the history of cancer research. Other
countries soon followed the lead of the United States, increasing
funding for cancer research. The massive investment created great
expectations, but progress toward a cancer cure has been slow.
The concept of targeted cancer therapy has led to the devel-
opment of many new agents, but these are unable to contend
with the complexity of cancer. In fact cancer comprises more than
100 diseases, with numerous variants. The tumor does not stand-
alone, but rather interacts intimately with itsmicroenvironment as
well as with the immune network, generating an organ-like entity.
The built-in genomic instability of the tumor makes its treatment
much like aiming at a moving target, since the wiring of the can-
cer “organ” changes continuously. We have come to realize that
the notions “Achilles’ heel” and “oncogene addiction” are reduc-
tionist notions, applying to a very narrow spectrum of diseases,
such as early stage chronic myelogenous leukemia (CML) and a
subclass of gastrointestinal stromal tumor (GIST), a subclass of
lung cancer and a few other cancers. In all these cases there is a
prominent oncogene coding for chimeric protein such as Bcr–Abl
in early CML, or mutated kinases like mutant forms of EGFR or
the chimeric protein EML4–ALK in subsets of non-small cell lung
carcinoma patients, and mutated BRaf in metastatic melanoma.
In all these cases the cell is “addicted” to the oncogenes and there-
fore blocking its protein product brings about dramatic responses.
However, within months or even less the disease recurs except
early CML, where the remission is long-term. Almost invariably,
the disease eventually breaks away from dependence on a single
oncogene, and the initially dominant target is demoted to one of
many. Long ago, we asserted the need for “smart cocktails” (Lev-
itzki, 1992) of targeted and non-targeted therapies. These “smart
cocktails” have to be modiﬁed continuously during the course of
treatment, as the cancer and its intimately associated microenvi-
ronment undergo continuous evolution. This is indeed the current
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modality of treatment, and it is showing incremental but steady
improvement in patient outcome. Dealing with a moving target,
which actually consists a continuously changing oncogenic net-
work poses a tremendous challenge to the therapist and cancer
researcher.
THE INTERACTION OF THE DEVELOPING CANCER WITH THE
IMMUNE SYSTEM
Cancer is a genetic disease, rooted in the gradual acquisition of
somatic mutations that eventually overcome the barriers to unreg-
ulated growth. The surveillance mechanisms that prevent cancer
include a variety of DNAdamage controlmechanisms,whichoften
trigger cellular senescence. The death of the emerging cancer cell
may also be induced by stress pathways that are turned on in
the mutated cells and/or by the p53 pathway. The immune sys-
tem also participates in the action. The immune system identiﬁes
newly emerging cancer cells, eliminating them.When this immune
surveillance is breached, cancer can develop.
It is now recognized that the immune system interacts in a
complex fashion with the tumor and can even cooperate with the
tumor. Thus, one speaks today about immunoediting rather than
immune surveillance. Immunoediting comprises three steps: elim-
ination, equilibrium, and escape. Initially, the innate and adaptive
immune systems eliminate emerging nascent tumor cells. Cancer
cells that are not eliminated attain equilibrium with the immune
network andbecomedormant.When tumordormancy is compro-
mised due to changes in the tumor, the tumor microenvironment
or the immune system, cancer cells escape the equilibrium, and
the tumor thrives. Factors that contribute to this continuous evo-
lution include the built-in genomic instability of the tumor cell
and changes that may occur in the immune system, for example as
the result of viral or bacterial infection. The complex interaction
between the emerging tumor and its microenvironment, which
includes the complex immune network, has been the subject of
intense research over the past few years. The newly revised classic
article “The Hallmarks of Cancer” now discusses the microenvi-
ronment as well as the immune system (Hanahan and Weinberg,
2011). Since researchers and clinicians alike recognize the dynamic
involvement of the immune systemat all stages of cancer initiation,
development, and progression, attention is now being devoted to
ﬁnding ways to compel the immune system to ﬁght cancer rather
than cooperate with it. A comprehensive review on the inter-
relationships between cancer and the immune system has been
published recently (Vesely et al., 2011).
HARNESSING THE IMMUNE SYSTEM TO TREAT CANCER
Killing cancer cells by the immune system has been on the agenda
for many years, but only in the last decade has real progress been
made (Blattman and Greenberg, 2004). Five approaches are being
adopted: (1) development of antibodies to attack cancer cells by
homing to cancer antigens. These anti-cancer antibodies are some-
times armed with cytotoxic chemicals, bacterial toxins, or labeled
with a radioactive element; (2) enhancing the action of anti-tumor
T cells, by means of antibodies or other methods; (3) development
of therapeutic vaccines; (4) development of prophylactic vaccines;
(5) development of strategies to target the anti-tumor action of the
immune system. In all cases attempts are being made to combine
these strategies with each other, as well as with other types of
targeted therapies and cytotoxic therapies.
Since these are emerging ﬁelds I shall not attempt to review all
the details but rather will refer the reader to key reviews that cover
various aspects of immune therapy. I will devote more space to our
ownattempts toharness the immune systemand target its action to
the tumor. Our chemical biological approach complements cur-
rent efforts by the scientiﬁc community to harness the immune
system against cancer. It differs from the other approaches in that
it is highly targeted to the tumor and does not evoke a systemic
immune response.
ANTIBODIES AGAINST CANCER ANTIGENS
Although monoclonal antibodies were discovered and developed
by Köhler and Milstein (1975), only in the 1990s did anti-cancer
antibodies start to move into the clinic. Chimeric monoclonal
antibodies, containing human constant domains and mouse vari-
able domains, have been developed for human therapy. Ritux-
imab/Rituxan/MabThera was the ﬁrst monoclonal antibody to
be developed for clinical use. Its success in the late 1990s cat-
alyzed the development of other anti-cancer antibodies, such as
Herceptin/trastuzumab targeting Her-2, Cetuximab/Erbitux tar-
geting EGFR, and alemtuzumab targeting CD52 for the treat-
ment of chronic lymphocytic leukemia (CLL), cutaneous T-cell
lymphoma (CTCL), and T-cell lymphoma. These are all partly
“humanized” mouse monoclonal antibodies, in which the only
mouse sequences are the ones responsible for speciﬁcity. More
recently fully humanized antibodies, such as the anti-EGFR anti-
body,panitumumab,have begun to enter the clinic. Humanization
of antibodies reduces their immunogenicity, increases their sta-
bility, and enhances their ability to induce antibody-dependent
cellular cytotoxicity (ADCC).
Rituximab/Rituxan has revolutionized the treatment of CD20-
positive, non-Hodgkin lymphomas (NHL). This antibody purges
leukemic cells as well as normal B cells. The anti-leukemic effect
is impressive and toxic effects slight, mainly due to the ability of
humans to live with no B cells, a fact that was not really appreciated
early on and is actually quite astonishing. Herceptin/Trastuzumab
is effective in the treatment of breast cancer patients whose tumors
strongly overexpress Her-2, especially when given early. The Her-
ceptin treatment is always given in combination with cytotoxic
therapy or the dual EGFR/Her-2 kinase inhibitor lapatinib. A sig-
niﬁcant number of patients with Her-2 positive breast cancer,
who are initially sensitive to Herceptin, later become refractory
to Herceptin treatment and succumb to the disease. Avastin,
the anti-vascular endothelial growth factor (VEGF) inhibitor, is
used in the treatment of metastatic colon cancer in combination
with chemotherapy. Similarly, Erbitux/Cetuximab, an anti-EGFR
antibody, is used in combination with chemotherapy or radia-
tion for the treatment of head and neck cancer, as well as other
cancers in which EGFR is overexpressed. Historically, the com-
bination of antibodies with other targeted agents against EGFR
was already demonstrated in 1991, when an EGFR-directed tyro-
sine phosphorylation inhibitor (tyrphostin) was combined with
an EGFR-directed antibody (Yoneda et al., 1991). Interestingly,
patients who do not express/overexpress EGFR on their tumors
were also reported to respond to Erbitux. In view of the success
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of anti-tumor antibodies it is not surprising that many more are
being developed and are on the way to the clinic.
Monoclonal antibodies operate by twomechanisms: ﬁrst, direct
inhibition of signal transduction by the receptor or the growth
factor at which the antibody is aimed and second, ADCC and
complement-dependent cytotoxicity (CDC). These two bystander
effects are extra beneﬁts provided by antibodies that are not pro-
vided by small molecular weight signaling inhibitors like tyrosine
phosphorylation inhibitors (tyrphostins; Levitzki, 1992). In fact,
combinations of antibodies with low molecular weight signal-
ing inhibitors are emerging as standard therapies. Combinations
of antibodies are also useful, even if they are against the same
molecular target, as long as they recognize different epitopes (see
below).
Antibody-dependent cellular cytotoxicity is mediated by the
Fc domain of an antibody. The humanized Fc domains on the
monoclonal antibodies bind to the Fc receptors on immune acces-
sory cells, mainly natural killer (NK) cells, but also neutrophils,
mononuclear phagocytes, and dendritic cells (DC). This interac-
tion activates the immune cells, which then engulf and destroy the
bound tumor cells. NK cells also release cytokines and chemokines
that inhibit cell proliferation and tumor-induced angiogenesis,
and induce the expression of major histocompatibility (MHC)
antigens on the tumor, enhancing tumor immunogenicity. Anti-
bodies that mediate ADCC also activate the complement system.
CDC leads to the direct killing of tumor cells through the for-
mation of a “membrane attack complex” (MAC). MAC gener-
ates a pore at the target cell membrane, leading to tumor cell
destruction. Various experiments demonstrate that the efﬁcacy of
Herceptin and Rituxan is due, to a signiﬁcant degree, to these
bystander effects. The intensity of the bystander effects depends
on the quality of the Fc domain. The absence of Fc receptors
or their diminished afﬁnities to the antibodies compromise their
efﬁcacy. For example it was shown, in pre-clinical experiments,
that experimental animals lacking Fc receptors on their immune
effector cells do not respond well to Herceptin since ADCC is
absent. It was also shown that polymorphisms in the IgG recep-
tors, CD16 (FcγRIIIa), and CD32a (FcγRIIa), predict how well
follicular lymphoma patients respond to rituximab. Also, in ani-
mals that lack elements of the complement pathway, rituximab
is not effective. Since the role of the Fc–Fc-receptor interaction
in the efﬁcacy of the antibody was recognized, second generation
antibodies against CD20with stronger afﬁnities for theCD20 anti-
gen have been generated, by mutating the Fc portion selected, to
enhanceADCC and CDC. These examples underscore the key role
that bystander effects play in the anti-tumor activities of antibod-
ies. It is therefore likely that other anti-cancer antibodies that are
being developed will also be engineered to enhance the bystander
anti-tumor effects.
Recently it was demonstrated that antibodies against different
epitopes of EGFR synergize to down-regulate EGFR and exhibit
strong anti-tumor effects in pre-clinicalmodels. In the case of Her-
2, a combination of antibodies has been examined in patients. Per-
tuzumab, which potently inhibits Her-2 dimerization and Her-2
mediated signaling, was combined with the Her-2-targeted mon-
oclonal antibody trastuzumab/Herceptin. These antibodies have
complementary mechanisms of action and result in enhanced
anti-tumor activity when combined, in pre-clinical models. Phase
II studies in humans have shown a good toxicity proﬁle and good
efﬁcacy. In view of the development of fast and effective means to
produce an array of antibodies targeted to a particular protein, it
is likely that using a mixture of antibodies against a single cancer
antigen will emerge as an effective strategy.
MANIPULATING THE IMMUNE RESPONSE TO TUMORS USING
ANTIBODIES
The immune system not only induces an immune response to
a speciﬁc target, but also involves a complex regulatory network
that attenuates the immune response in order to avoid autoim-
mune reactions. Recognizing the self-restraining action of the
immune response, strategies to down-regulate the attenuation
of the immune response, thus elevating the innate anti-tumor
immune response are being developed (Korman et al., 2006);
(Peggs et al., 2008). The most advanced and dramatic example
of this strategy is the development of ipilimumab and its recent
approval for clinical use.
Ipilimumab is an antibody against cytotoxic T-lymphocyte-
associated 4 (CTLA-4). CTLA-4 raises the signal threshold for
T-cell activation, leading to the attenuation of T-cell activation.
Clinical trials have shown efﬁcacy for CTLA-4 blocking antibod-
ies (Hodi et al., 2010) in melanoma, and renal cell carcinoma.
Ipilimumab received FDA approval in 2011 for the treatment of
metastatic melanoma. The use of antiCTLA-4/ipilimumab is now
being evaluated for the treatment of other tumors. Using a similar
approach attempts are being made to manipulate immune check-
points regulated by B7H1, B7H4, OX-40, CD137, CD40, and PD1,
enhancing anti-tumor immune responses.
The development of agents that temper with immune check-
points is attractive, since in principle such agents can be utilized for
many types of tumors. Clearly, dosing and combinationwith other
agents will be different for every type of cancer and will have to
be individualized. An important caveat is that such general agents
can cause severe autoimmune toxic effects, as has already been
observed. Better understanding of the complex regulation of the
immune response and more clinical experience is likely to bring
a gradual improvement of this approach. It is likely that for every
cancer the therapeutic window will be deﬁned for each individual
patient. A certain amount of toxicity (e.g., rash) is an indication
of efﬁcacy and may be used as a possible early generation bio-
marker. Manipulation of the immune checkpoints on T cells, NK
cells, macrophages, and DC, can in principle amplify the effects
of ADCC and vaccines, leading to clinically useful host-generated
anti-tumor effects. It is therefore likely that antibodies that inhibit
the moderating signals of the immune response will be combined
with other anti-tumor therapeutic modalities.
USING ANTIBODIES TO TARGET THERAPY
Antibodies can be used to bring non-speciﬁc therapy directly to the
tumor site, thus reducing toxic side effects induced by the systemic
application of the cytotoxic agent.
Antibody–drug conjugates
Attempts have been made for many years to target cytotoxic
agents to cancer cells, using antibodies. Recently such an anti-
body conjugate, Brentuximab vedotin, was approved for clinical
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use. Brentuximab vedotin is a chimeric monoclonal antibody,
which targets CD30 and possesses three to ﬁve units of the antim-
itotic agent monomethyl auristat (MMAE) bound to the protein.
MMAE is responsible for the anti-tumor activity. In a clinical
trial, 34%of patientswith refractoryHodgkin lymphoma achieved
complete remission and another 40% had partial remission with
tumor reductions in 94% of patients. In anaplastic large cell lym-
phoma (ALCL), 87% of patients had tumors shrink at least 50%,
and 97% of patients had various extents of tumor shrinkage.
Radioimmunotherapy
Antibodies can be used to target radioisotopes to the tumor site.
This form of therapy is known as radioimmunotherapy (RIT).
A few radioactively labeled antibodies are already in the clinic,
such as 90Y-labeled Rituxan (Zevalin) and 131I-labeled labeled
Rituxan (Bexxar). Both radioactively labeled anti-CD20 antibod-
ies are used in patients with B-cell NHL who do not respond to
the regular anti-CD20 antibody rituximab. In principle, radio-
labeled antibodies can be also used to treat metastases of solid
tumors to the bone marrow and lymph nodes, which are acces-
sible to circulating mAbs. A number of radiolabeled antibodies
are in development to treat prostate cancer, for example. However,
many solid tumors are radio-resistant or develop radioresistance
and therefore are not as accessible as hematological malignancies
to RIT.
Immunotoxins
Antibodies and ligands can be used to target toxins to the tumor
site. The ﬁrst immunotoxins were made by chemically conju-
gating antibody to toxin, but today recombinant fusion proteins
are used. Pseudomonas exotoxin and Diptheria toxin have been
successfully incorporated into recombinant immunotoxins (Pas-
tan et al., 2006). Both of these toxins are ADP ribosylases that
covalently modify elongation factor 2 (EF2), inhibiting protein
synthesis, and leading to cell death. The fusion protein is molec-
ularly engineered such that the natural binding domains of these
bacterial toxins are deleted, to prevent binding to normal cells. The
recombinant protein consists of a tumor-targeting ligand or anti-
body, and the translocation and catalytic domains of the toxin.
Following internalization into the tumor cell, the immunotoxin
is cleaved within the translocation domain, releasing the catalytic
domain. RFB4 (dsFv)-PE38 (BL22), a recombinant immunotoxin
containing an anti-CD22 variable domain (Fv) fused to truncated
pseudomonas exotoxin,was found to be successful in treating drug
resistant (purine analog treatment) hairy cell leukemia patients.
One problem that limits the use of fusion proteins for therapy
is the development of neutralizing antibodies. Although most
patients develop anti-denileukin diftitox antibodies, even after
one cycle of treatment, some patients continue to respond after
re-treatment. The Pastan–Bigner groups also reported a posi-
tive clinical outcome with a recombinant Pseudomonas exotoxin
targeted to the EGFR by fusion with TGFα (Sampson et al.,
2005).
THERAPEUTIC VACCINES
The immune system is educated and trained to identify, seek, and
destroy invading pathogens, and does it with great efﬁciency. It
is however much less effective at recognizing tumor antigens and
destroying them, partly because tumors express antigens common
to normal cells such as EGFR or Her-2, only at higher levels.
Furthermore, many tumors evade the immune system by failing
to express antigens that can be recognized by the immune sys-
tem, and/or they develop various strategies that interfere with the
execution of the anti-tumor immune response.
Although vaccines have a strong track record in ﬁghting serious
infections, such as polio,mumps, and measles, they have so far had
limited success in the treatment of cancer. Vaccines work best with
soluble antigens, and are much less efﬁcacious against bulky, solid
tumors. Moreover, cancer cells change continuously, due to their
genomic instability and therefore change their antigen presen-
tation and/or HLA markers. Furthermore, cancer cells frequently
secrete immunosuppressive cytokines, such asTGFβ and IL-10 (see
Stat3 as a Target). In spite of these caveats, a number of therapeutic
vaccines are at various stages of development, but the results so far
are not too encouraging. Numerous vaccines against peptides that
represent various cancer antigens have been tested, with rather
limited success. Several cellular vaccines, which present multiple
antigens, are also in advanced trials, with the hope that multiple
tumor antigens will boost the anti-tumor activity of emerging vac-
cines. So far the success of vaccines has been limited but success
may be emerging. For example, Sipuleucel-T is an active cellu-
lar immunotherapy against castration-resistant prostate cancer
(Kantoff et al., 2010). The vaccine consists of autologous periph-
eral blood mononuclear cells (PBMCs), which include antigen-
presenting cells (APCs) that have been activated ex vivo with a
recombinant fusion protein. The activating protein, called PA2024,
consists of a prostate antigen, prostatic acid phosphatase, fused to
granulocyte–macrophage colony-stimulating factor, an immune
cell activator. This vaccine showed clinical efﬁcacy and therefore
obtained FDA approval in 2010. It should be stressed however
that the survival beneﬁt reported for this vaccine is of a few
months only.
A recent report claims thatwomenwithHPV-16-positive, grade
3 vulvar intraepithelial neoplasia respond to vaccination by a syn-
thetic long-peptide vaccine against the HPV-16 oncoproteins E6
and E7 with a few complete responses (Kenter et al., 2009).
We now understand that one of the main reasons vaccines have
not been successful is that the tumor microenvironment is not
conducive to the migration and optimal activation of DCs, so
the ensuing immune response is weak and ineffective. Thus in
order to stimulate an anti-tumor immune response one has to
channel the tumor antigens into the appropriate DC subset and
induce the DCs to develop into potent immunostimulatory APCs.
In order to enhance the anti-tumor immune response, attempts
are being made to stimulate the immune system by the activation
of Toll-like receptor 9 (TLR9; Hennessy et al., 2010). TLR9 recog-
nizes unmethylated CpG in DNA molecules, common in bacteria,
and rare in vertebrates. TLR9 is expressed intracellularly, within
the endosomal compartments of DCs, B lymphocytes,monocytes,
and NK cells. TLR9 signals initiate pro-inﬂammatory reactions
that result in the production of cytokines such as interferon type
I and IL-12. Arousal of the innate immune system is likely to tilt
the tumor microenvironment toward preventing the tumor from
evading therapeutic vaccines. Another approach is to prepare DCs
Frontiers in Oncology | Cancer Molecular Targets andTherapeutics February 2012 | Volume 2 | Article 4 | 4
Levitzki Immune therapy of cancer
for anti-cancer vaccines, in the presence of interferon α (for review
see Moschella et al., 2010).
VACCINATION AS A CANCER PREVENTION STRATEGY
Several cancers are strongly associated with viral infection. There-
fore, one strategy for cancer prevention is to vaccinate against
viruses that cause cancer. Indeed, the vaccine against hepatitis B
virus (HBV; Blumberg, 2010) is expected to reduce the incidence
of HBV-related hepatocellular carcinoma. Intensive attempts are
also being made to develop a vaccine against hepatitis C virus.
In 1984, large-scale hepatitis B vaccination of newborns began in
Taiwan. During the years 1984–1999 the incidence of childhood
liver carcinoma decreased: a 62–70% decline in mortality due to
liver carcinoma among children has been reported. In the western
world cervical cancer is the fourth leading cause of cancer-related
death in women, after breast cancer, lung cancer, and colon cancer.
In developing countries, where routine Pap smears are less wide-
spread, cervical cancer is the leading cancer among women. The
recent introduction of vaccines against the most common high-
risk strains of human papilloma virus (HPV) is expected to reduce
mortality from cervical cancer, which is caused by this virus and
is the major cause of cancer-related deaths among women in the
developing world.
CELLULAR IMMUNE THERAPY
This is actually a form of individualized immune therapy. In
this approach one isolates CD8+ cytotoxic T cells directed at the
tumor from a patient’s own tumor (tumor inﬁltrating lympho-
cytes, TILs), and expands the cells in culture ex vivo. One can
even sort out the T cells that recognize a speciﬁc tumor antigen.
While ex vivo, the T cells can also be genetically engineered to
home more effectively to the tumor and even enhance their tumor
killing efﬁcacy.
Genetically modiﬁed T cells can originate from the tumor itself
or from normal T cells of the patient. One engineers the T-cell
receptor such that when reintroduced into the patient the T cells
will home to the tumor and kill it. The advantage of using normal
T cells over TILs is that one is not limited by the relatively small
number of TILs andmore importantly,one does not dependon the
necessary access to the tumor to get TILs, which is not always pos-
sible. It is hoped that the identiﬁcation of speciﬁc tumor antigens
for each patients will enable individualized T-cell therapy.
Before reintroduction of the T cells, the patient is treated with
systemic chemotherapy or irradiation to deplete him of lympho-
cytes, and then the anti-tumor T cells are reintroduced into the
patient. The approach has been used with a measure of success in
the treatment of metastatic melanoma (Dudley et al., 2008; Rosen-
berg et al., 2008) and in CLL. One problem is the tendency of the
T cells to undergo apoptosis, once they encounter the tumor. This
can be addressed and even overcome by the co-administration of
IL-2, known to enhance the survival of T cells and to promote their
proliferation. Cancer patients also suffer from lowered numbers
of CD4+ T helper cells, which support the survival of cytotoxic T
cells. CD4+cells are harder to expand ex vivo than CD8+ cells, and
adoptive transfer of CD4+ cells is so far less advanced than that
of CD8+ cells. Since the immune system is conducive of tumor
development and maintenance, when diagnosed it is important to
break immune tolerance in order to make cellular therapy more
effective. This canbe achievedbyusing cyclophosphamide thatwas
found to enhance the efﬁcacy of TILs (for reviews see Moschella
et al., 2010; Sistigu et al., 2011).
BISPECIFIC ANTIBODIES TO ENGAGE CYTOTOXIC T CELLS
Cytotoxic T cells can be induced to attack a tumor by means of
bispeciﬁc antibodies, which have speciﬁcity both for T cells and
for the tumor (Wolf et al., 2005). These antibodies are also known
as bispeciﬁc T-cell engagers (BiTEs). One such antibody is Bli-
natumomab/MT103, a dual speciﬁcity antibody. Blinatumomab
combines two binding sites: a CD3 site for T cells and a CD19
site for the target B cells. The drug works by linking these two
cell types and triggering T-cell activation, which exerts cytotoxic
effects on the target malignant B cells. In a phase I clinical trial
of blinatumomab, patients with NHL showed tumor regression
and even complete remission. At present the bispeciﬁc antibody is
being tested on acute lymphoblastic lymphoma (ALL).
Future experiments will assess the use of bispeciﬁc antibod-
ies against solid tumors. A bispeciﬁc antibody, MT110, directed
against an epithelial cell adhesion molecule (Ep-CAM/CD326)
that is overexpressed onmost human carcinomas and against CD3,
is being assessed for therapeutic potential for the treatment of
cancers of the colon, breast, pancreas, and prostate. Pre-clinical
experiments using animal models are highly promising, but only
clinical trials, which are still ongoing, will establish efﬁcacy. In
order to minimize autoimmune effects, MT110 was designed to
have only moderate afﬁnity for Ep-CAM (Amann et al., 2009).
RECRUITING THE INNATE IMMUNE SYSTEM TO ATTACK THE
TUMOR
THE PRINCIPLE
The tumor microenvironment is not conducive to attack by the
immune system. Tumors that are in equilibrium with the immune
system remain dormant, but tumors that escape immune con-
trol run wild. Tumors utilize a number of strategies to evade the
immune system. One important mechanism, common to many
different cancers, is the secretion of cytokines, such as IL-10,
TGFβ, and VEGF. Other mechanisms, triggered by biochemical
pathways emanating from the tumor cell, include the expression
of decoy receptors such as a non-signaling Fas ligand, disabling
apoptotic pathways, and the down-regulation of MHC type I
molecules, leading to the evasion of recognition by CD8+ CTL.
The systemic anti-tumor immune response can be enhanced by
using ligands such as CpG to enhance TLR9 (see Therapeutic
Vaccines). Activation of TLR9 is not targeted speciﬁcally to the
tumor, but rather enhances overall immune responsiveness. As
indicated above, the activation of TLR9 sensitizes a tumor to all
tumor-targeted immune therapies. Therefore, it is likely that TLR9
agonists will ﬁnd their place in immunotherapeutic regimens as
well as other therapeutic modalities that can be augmented by the
utilization of TLR9 agonists.
We decided to develop an immunotherapeutic strategy that
would be highly focused on the tumor and have limited general
immune effects. Recognizing that antibodies induce a bystander
effect at the tumor site and therefore are more efﬁcacious than
tyrphostins, we sought a strategy to enhance the bystander effect
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at the tumor site, whilst still using the receptor tyrosine kinase
as the tumor-speciﬁc target. We sought a simple and inexpensive
approach.
The synthetic long chain dsRNA,PolyIC, has strong anti-tumor
activity and has been used as an immune adjuvant for many years
(Talmadge et al., 1985; Salem et al., 2005, 2006; Kumar et al., 2008;
Navabi et al., 2009; Okada et al., 2011). We therefore considered
this molecule for our efforts. In a recent trial, type1 polarized DCs
were loaded with synthetic peptides for glioma-associated anti-
gen plus polyIC complexed with polylysine. There was a positive
immune response in 58% of the 22 recipients, and sustained com-
plete remission was reported in one patient (Okada et al., 2011). In
another clinical situation, poly AU showed an improvement in 20-
year survival rates in a subset of breast cancer patients with tumor
cells that expressed TLR3(Lacour et al., 1991). There are more
than 24,000 entries in Google Scholar when one inserts “PolyIC
Adjuvant Cancer.” The response of metazoan cells to dsRNA is
a mechanism utilized mostly, but not exclusively, against dsRNA
viruses and ssRNAviruses that generated sRNAduring replication.
Long chain dsRNA induces strong anti-apoptotic effects within
the cell. The activation of PKR by the dsRNA leads to the phos-
phorylation of eIF2α and a halt in protein translation. dsRNA
also stimulates RNAaseL, contributing to the inhibition of trans-
lation. In addition to the direct intracellular pro-apoptotic effects
of long chain dsRNA, there are strong bystander effects on neigh-
boring cells, mostly mediated by TLR3, retinoic acid-inducible
gene I (RIG-1), and melanoma differentiation-associated gene 5
(MDA5) (Figure 1).
The tumor cells that internalize the dsRNA are induced to
secrete interferons alpha and beta and other cytokines that attract
T cells and NK cells – which in turn secrete additional cytokines –
to the locality. The activation of PKR and of the innate immune
network is rapid and localized to the tumor.We therefore expected
that activation of innate immunitywould be focused on the tumor,
with minimal activation of the overall immune system.
The systemic application of long chain dsRNA such as PolyIC
is toxic, mainly due to strong systemic immune reactions. This is
why PolyIC and Ampligen (a complex of PolyIC with polylysine)
are not used systemically but only in the adjuvant setting. Still,
we were highly impressed by the profound effects of PolyIC and
therefore decided to formulate it in a way that it would be targeted
to the tumor. It was clear to us that we needed to develop PolyIC-
carrying vectors that would home selectively to the tumor and be
internalized quickly into the tumor, to induce strong anti-tumor
effects and avoid systemic toxicity. To this end, the vector needed to
possess a ligand that would guide PolyIC to a speciﬁc receptor on
the tumor, such that receptor-mediated endocytosis would rapidly
lead to internalization of the PolyIC. Thus, the ligand would act as
a targeted Trojan Horse. Another pre-requisite was that the recep-
tor should be expressed at high levels on the tumor and much less
on normal tissues, opening a therapeutic window.
A suitable receptor is the EGFR, for which the group of
Ernst Wagner (Ludwig Maximilian University, Munich) has
developed synthetic chemical vectors bound to EGF, and they
use these to introduce genes into EGFR-overexpressing tumor
cells. Using their vectors, we have been developing the Trojan
horse approach to eradicate tumors, using polyethyleneimine–
FIGURE 1 |The targets of dsRNA.TLR3 recognizes dsRNA extacellularly
or in endosomal compartments. TheTLR3TIR domain is associated with
the adaptor molecule TRIF, which upon ligation activates the protein kinases
TBK-1 and IKKe. IRF-3 is phosphorylated byTBK-1 and IKKe on C-terminal
serines, leading to its dimerization and translocation into the nucleus. Active
IRF-3 induces transcription from the IFN-β promoter. Intracellular dsRNA is
recognized by the RNA helicase RIG-I (or MDA5), which activatesTBK-1 and
IKKe via its CARD domain, leading to IRF-3 activation as well. Both pathways
also activate NFκB by mechanisms that are not fully understood yet.
Secreted IFN-β binds to the IFN receptor (IFNR) leading to transcriptional
activation of ISGs (interferon stimulated genes), such as IRF-7. IRF-7 further
stimulates transcription from the IFN-α and -β promoters in a positive
feedback loop. In addition to these targets, which are responsible for the
activation of the immune system dsRNA binds to the enzyme dsRNA
dependent protein kinase, PKR. The activation of PKR leads to the
phosphorylation of the eIF2a, leading to the inhibition of protein translation.
polyethyleneglycol–EGF based vectors (Figure 2). Remembering
that tumor cells are much more vulnerable than normal cells to all
stresses (Benhar et al., 2002),we hypothesized that we could deﬁne
a wide enough therapeutic window to affect tumor cells almost
exclusively, sparing the normal cells surrounding the tumors.
The strategy, if successful, would have an advantage over other
immunotherapeutic approaches, since both the innate immune
system and the adaptive immune system would be activated and
directed to the tumor. Moreover, this strategy can, in principle,
overcome immunoinhibitory mechanisms developed by many
cancers, due to the overwhelming immune activating effects of
polyIC as well as to the fast-acting nature of polyIC.
THE ERADICATION OF EGFR-OVEREXPRESSING TUMORS IN
PRE-CLINICAL ANIMAL MODELS
Initially we utilized PolyIC complexed with branched-
polyethyleneimine–polyethyleneglycol–EGF (PolyIC/brPEI–PEG–
EGF) mixed with brPEI–melittin (Shir et al., 2006). These two
entities mix in nanoparticles that home to EGFR and internalize
into the cell. Melittin was used to enhance endosomal release, to
enable the PolyIC to bind to and activate PKR, which resides in
the cytoplasm. Other targets for dsRNA, such as TLR3, RIG-1, and
MDA5, should be activated in the endosome (Figure 1). Using
this nanoparticle we demonstrated the complete eradication of
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FIGURE 2 | Chemical vectors targeting the EGFR.The core structural
elements of the chemical vectors targeting the EGFR consists of branched
polyethyleneimine tethered by polyethyleneglycol to an EGFR homing
ligand EGF or a peptide GE11. The tetraconjugate possesses a melittin
moiety that facilitates endosomal release. The triconjugate is composed of
a linear and shorter polyethyleneimine molecule tethered to the EGFR
homing ligand via a short polyethyleneglycol.
intracranial tumors generated in mice from glioblastoma cell lines
that overexpressed EGFR. The particles were applied locally to the
tumor site, using Alzat pumps. Even tumors 15mm3 in size were
completely eradicated by a 3-day treatment.
The vector did not kill glioblastoma cells that overexpressed
mutated Δ(2–7) EGFR (EGFRvIII) receptors, which do not bind
and therefore do not internalize the PolyIC-loaded EGFR hom-
ing vector. Strikingly, when cells overexpressing wild type EGFR
were mixed with cells overexpressing Δ(2–7) EGFR the latter were
killed: intracranial tumors comprising 50% cells overexpressing
EGFR and 50% Δ(2–7) EGFR, were eradicated. The cells that
overexpressed wild type EGFR and internalized the polyIC initi-
ated strong bystander effects (Figure 3), which led to the demise
of the mutant EGFR-expressing cells. Notably, the nude mice used
in these experiments lacked T cells, yet they mounted a partial
bystander response, sufﬁcient to cure the experimental animals.
These results show that the bystander effect is effective and allows
the complete cure of animals that harbor large intracranial tumors,
by a 3-day treatment. At the same time we did not observe any
damage to the normal brain tissue during treatment. Further-
more, the necrotic tissue bordering the tumor in the brain also
disappeared.
At this point an improved version of the vector was intro-
duced: a tetraconjugate, Melittin–brPEI–PEG–EGF (MPPE), in
which the melittin was incorporated into the EGF homing vec-
tor (Figure 2; Shir et al., 2006). The tetraconjugate proved to be
highly effective and quickly replaced the mixture of the triconju-
gate withMel-PEI. The rapid eradication of intracranial tumors by
local application of the EGFR-targeted PolyIC convinced us that
the strategy could be moved to clinical development for the local
treatment of EGFR-overexpressing tumors, not only in the brain.
It should be noted that in human GBM one ﬁnds a heterogeneous
mixture of cells, including many types of pluripotent cells/cancer
stem cells that may or may not express high levels of EGFR (Maz-
zoleni et al., 2010). Elimination of the EGFR-overexpressing cells,
using AG 1478, a selective EGFR tyrphostin, enables the EGFR-
negative cells to survive and thrive (Mazzoleni et al., 2010). It is
likely that treatmentwith theEGFR-targetedPolyIC,will also elim-
inate the EGFR-negative GBM cells, limiting or even preventing
tumor recurrence (Figure 3).
We next decided to adapt the EGFR-targeted dsRNA killing
strategy to eradicate disseminated EGFR-overexpressing tumors,
since humans usually succumb to disseminated tumors. Toward
this end we established a model for disseminated tumors: we
injected two million cells intravenously to SCID mice and waited
for tumors to develop in various organs. Treatment with the vector
PolyIC/MPPE began 5, 10, or 15 days after intravenous cell injec-
tion. Complete eradication – deﬁned as survival for more than
1 year – of 5- or 10-day-old disseminated tumors derived from
A431 cells or MD-MB468 was achieved. The animals were treated
for 10 days with two 1-day intermissions, thus avoiding toxicity.
Large (∼200μm)15-day-old tumorswere only partially inhibited:
60% of animals with A431 tumors survived over 1 year; animals
with disseminatedMD-MB468 tumors showed long-term survival
but no complete tumor eradication (Shir et al., 2011).
The SCID mouse model does not enable us to examine the full
capacity of our dsRNA therapy, because SCID mice have extremely
deﬁcient immune systems. Our next step, therefore, was to recon-
stitute the SCID mouse immune system with human PBMCs
and use these mice for the study of targeted PolyIC therapy of
disseminated cancers. When SCID mice harboring 15-day EGFR-
overexpressing tumors were treated with EGFR-targeted PolyIC,
and PBMC were introduced, the mice were completely cured by
a short treatment (4 days; Shir et al., 2011). The mice survived
for over a year, with no tumor recurrence. Furthermore, tumors
not expressing EGFR were oblivious to the treatment and animals
with these tumors succumbed to the disease. Interferon gamma,
TNF-alpha and IL-2 were generated within the tumors themselves
during the treatment, but few cytokines were detected in the blood
stream. We also demonstrated that immune cells inﬁltrated the
tumor. These ﬁndings validated the targeted nature of the innate
immunity aroused by the EGFR homing vector armed with PolyIC
(Shir et al., 2011) (Figure 3).
In cellular studies we found that the PolyIC synergizes with
immune cells recruited to PolyIC-treated tumor cells, to induce
tumor cell death. In the disseminated tumor model, the direct
killing effect of PolyIC combined with the effect of the PBMC-
derived immune cells attracted to the PolyIC-treated tumors, led
to the complete elimination of the disseminated tumors. Activated
immune cells converging on the tumor enhanced the bystander
effect, killing even those cancer cells that were not attacked directly
by the PolyIC.
The fast immune response that we observed strongly suggests
that innate immunity is the primary player in the animal model we
have constructed. Inﬁltration of APCs, such as macrophages, into
the tumor and induction of class I and class II MHC by IFNs even-
tually should lead also to an adaptive immune response against the
tumor. In our experiments, we did not observe systemic immuno-
toxic reactions, most likely because the tumor acted as a “sink,”
quickly eliminating the vector from the blood stream, and because
the treatment was short (4 days).
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FIGURE 3 |The pattern of the recruitment of the immune system to the tumor.The dsRNA internalized into the tumor cells binds to dsRNA-binding
signaling proteins, which then activate a plethora of signaling pathways, leading to the recruitment of immune cells to the tumor as well as to apoptotic
programs (Figure 1).
In principle,EGFR-targetedpolyIC canbe combinedwith other
cancer immunotherapies available today. These include cancer
vaccines and cancer-targeted (engineered or extracted) T cells.
To mediate anti-tumor effects in vivo, cancer-targeted T cells must
travel to the tumor site, extravasate from the circulation, and then
mediate effector functions to cause destruction of cancer cells.
IP-10 and Gro-α are strongly induced by targeted polyIC selec-
tively in tumor cells, which should facilitate both trafﬁc to the
tumor and extravasation of T cells. Similarly, the polyIC treat-
ment induces IFNs, which should enhance T-cell-mediated cancer
killing. The absence of an immunocompetent mouse model of
EGFR-overexpressing cancer currently precludes a study of the
activation of the mouse’s own immune system by polyIC/MPPE.
Nonetheless, our data suggest that systemic treatment of EGFR-
overexpressingmetastatic tumors with EGFR-targeted polyICmay
lead to a complete cure, in patients with a functional immune
system.
In its latest version, the PolyIC homing vector has been re-
engineered to eliminate the melittin. The branched polyethyl-
eneimine (brPEI) was replaced by a linear version of PEI and the
PEG shortened, producing the triconjugate L-PEI (22 kDa)-PEG
(2kDa)-EGF (Figure 2) (PPE; Schaffert et al., 2011).
The re-engineered vector was as good as the melittin-
containing tetraconjugate MPPE. The PolyIC/L-PEI–PEG–EGF
(PolyIC/PPE) shows excellent efﬁcacy and is now replacing the
tetraconjugate in our experiments and has been recently adopted
for advanced pre-clinical development by Bioline Rx. We have
also shown recently that EGF can be replaced by an EGFR-binding
peptide, GE 11, identiﬁed by phage display (Li et al., 2005). The
vector PEI–PEG–GE11 (Figure 2) showed enhanced transfec-
tion into EGFR-overexpressing tumor cells, including glioblas-
toma and hepatoma cells, but without causing EGFR activation
(Schafer et al., 2011). PolyIC/PEI–PEG–GE11 was less selective,
however,when compared with PolyIC/PPE as an anti-tumor agent
(Abourbeh et al., 2012). The absence of EGFR activation by GE1
(Schafer et al., 2011) may be advantageous, but it is not clear
whether the very short exposure of a patient to an EGFR-activating
vector is actually a problem. The presence of TGFα in the recom-
binant pseudomonas toxin-TGFα did not prevent the FDA from
allowing its successful use in treating GBM patients, in clinical
trials (Pastan et al., 2006). We therefore believe that PolyIC/PPE
is suitable for clinical development, while we are continuing to
evaluate PPGE11 (Abourbeh et al., 2012) in pre-clinical models.
The chemical vector we utilize is actually built like Lego, such
that the homing ligand can be replaced, with the other elements
remaining constant. Any tumor that overexpresses a surface pro-
tein that can be internalized upon ligand binding is a candidate for
targeted PolyIC therapy, once the coupling conditions have been
optimized for the relevant ligand. Table 1 depicts tumors that
overexpress receptor proteins that can in principle be targeted by a
vector similar to the ones used for targeting EGFR-overexpressing
tumors.
STAT3 AS A TARGET
Stat3 plays a crucial role in tumor development at multiple lev-
els. Stat3 functions as an oncoprotein in tumor cells and inhibits
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Table 1 | Examples of cancers with overexpressed growth factor
receptors.
Receptor for Cancer
EGF Head and neck, breast, colon, lung, prostate, kidney, ovary,
brain, pancreas, bladder
PDGF Brain, prostate
PSMA Metastatic prostate cancer, neovasculature of solid tumors
Her-2 Breast, cervical, lung
FGF Melanoma, Kaposi sarcoma, pancreatic
Transferrin Leukemia, brain, colon, kidney, bladder
EGF, epidermal growth factor; PDGF, platelet derived growth factor; IGF, insulin
like growth factor; FGF, ﬁbroblast growth factor.
the anti-tumor effects of immune cells, tilting the immune system
toward cooperation with the tumor cells. A comprehensive dis-
cussion of the role of Stat3 in the interaction between the tumor
and the immune system is given in (Yu et al., 2007, 2009). We
shall describe brieﬂy the action of Stat3, since we believe that Stat3
inhibition can be combined effectively with targeted PolyIC. Stat3
mediates crosstalk between tumor cells and immune cells, forming
an immunosuppressive network in many tumors, including GBM.
Stat3 is persistently activated in many kinds of cancer, in both
the tumor cells and the tumor-associated stromal cells, including
diverse immune cells. Activated Stat3 promotes the expression of
numerous immunosuppressive factors, such asVEGF, interleukin-
10 (IL-10), IL-6, and IL-23. The receptors formany Stat3-regulated
factors in turn are Stat3 activators andare expressedby various cells
of hematopoietic origin. This feed-forward loopof Stat3 activation
underlies the crosstalk among tumor cells and diverse immune
cells in the tumor microenvironment (Yu et al., 2007, 2009).
Although Stat3 is a well-known transcription factor, more recent
studies have demonstrated its ability to inhibit the expression
of a large number of Th1 immunostimulatory genes. For exam-
ple, Stat3 inhibits the expression of the MHC class II molecules,
CD80, CD86, and IL-12, by DCs. This prevents DC maturation,
which is required to stimulate the anti-tumor effects of CD8+ T
cells and NK cells. Consequently, persistent activation of Stat3 in
tumor cells and in tumor stromal immune cells is associated with
profound immunosuppression. Furthermore, immature myeloid
cells that accumulate in the tumor produce VEGF, bFGF, and
other angiogenic factors in a Stat3-dependent manner, promoting
tumor vascularization, or angiogenesis. Tumor vascularization, in
turn, protects the tumor cells from apoptosis and counteracts the
interferon-γ-dependent effects of CD8+ T cells. Thus, inhibition
of Stat3 should be effective in treating many forms of cancer.
A number of strategies for Stat3 inhibition are being followed,
including low molecular weight inhibitors that target Stat3 dimer-
ization, inhibiting Stat3 binding to DNA, and siRNA. Stat3 siRNA
linked to CpG oligonucleotide, the ligand for TLR9 receptor, was
effective at inhibiting Stat3 in myeloid cells and B cells in vivo,
activating the immune system to exert its anti-tumor activity
(Kortylewski et al., 2009). It is likely that a combination of targeted
dsRNA such as PolyIC with emerging Stat3 inhibitors will have
additive or even synergistic effects. Stat3 inhibition is expected to
disarm the shield of the tumor and its microenvironment, sen-
sitizing the tumor to other forms of therapy, including targeted
PolyIC therapy.
CONCLUDING REMARKS
In the last few years the utilization of monoclonal antibodies to
treat various malignancies has accelerated at a much higher pace
than the development of new medicinal compounds. This trend
reﬂects the recognition that harnessing the immune system is
an effective way to attack cancer. An important feature of anti-
body action is the induction of ADCC, which brings about the
demise of tumor cells neighboring the targeted tumor cell. This
feature is missing from small molecular weight signal transduc-
tion inhibitors. In this review we argue that one could upgrade
the bystander effects induced by antibodies if one were able to
target the immune stimulator PolyIC to the tumor. This strategy
would bring about strong anti-tumor activities, allowing a short
and effective treatment. The strategy can be utilized to treat tumors
that overexpress proteins that internalize upon ligandbinding. The
prevalence of such tumors is very wide, so this strategy should be
applicable to the treatment of many types of cancer.
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